Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry
Nguyen-Dumont Tu, Fleur Hammet, Maryam Mahmoodi, Helen Tsimiklis, Zhi L Teo, Roger Li, Bernard J Pope, Mary Beth Terry, Saundra S Buys, Mary Daly, John L Hopper, Ingrid Winship, David E Goldgar, Daniel J Park, Melissa C Southey
Breast Cancer Research and Treatment | SPRINGER | Published : 2015
Awarded by National Cancer Institute (USA)
Awarded by Australian National Health and Medical Research Council (NHMRC)
Awarded by VLSCI
TN-D is a Susan G. Komen for the Cure Post-doctoral Fellow. ZLT was supported by Postgraduate Scholarships provided by the Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne and the National Health and Medical Research Council (NHMRC, Australia). RL is supported by UROP, a program of Biomedical Research Victoria, by the Victorian Life Sciences Computation Initiative (VLSCI) and by the Department of Pathology, The University of Melbourne. MCS is an NHMRC Senior Research Fellow. The Utah, New York, and Philadelphia sites of the Breast Cancer Family Registry were supported by Grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), or does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. This work was supported by the Australian National Health and Medical Research Council (NHMRC) (APP1025879 and APP1029974), the Victorian Breast Cancer Research Consortium and by a VLSCI Grant (number VR0182) on its Peak Computing Facility, an initiative of the Victorian Government.